L’impact des interventions de lutte contre le paludisme, ces dernières années, a fortement modifié la répartition géographique du fardeau de la maladie. Cette nouvelle configuration impose une stratification plus opérationnelle permettant d’adapter les interventions aux caractéristiques ...pidémiologiques locales. L’approche focalisée des interventions spécifiques par zone devient alors un impératif.
Le présent PSN pour la période 2016 - 2020 clarifie ces nouvelles orientations strategiques.
more
30/03/2020 (V1) 06/04/2020 (V2)
Selon l’Organisation Mondiale de la Santé (OMS), la COVID-19 est la maladie infectieuse causée par le dernier coronavirus qui a été découvert. Ce nouveau virus était inconnu avant l’apparition de la flambée à Wuhan en Chine en décembre 2019.
This study highlights the challenges and areas in need of improvement as perceived by CHWs and beneficiaries, in regards to a nationwide scale-up of CHW interventions in a resource-challenged country. Identifying and understanding these barriers, and addressing them accordingly, particularly within ...the context of performance-based financing, will serve to strengthen the current CHW system and provide key guidance for the continuing evolution of the CHW system in Rwanda.
more
Demographic and Health Surveys, Working Paper
A case study from Bosnia and Herzegovina Eurasian Harm Reduction Network
The case study was prepared by Samir Ibisevic, President of PROI between March and June 2016 and edited by Graham Shaw.
EHRN is grateful to all who contributed to this document, especially: Dr. Serifa Godinjak, Chairperson... of Country Coordinating Mechanism; Dr. Zlatko Cardaklija, HIV Coordinator for the Federation of Bosnia and Herzegovina (BiH); Dr. Nesad Seremet, Head of the HIV program, United Nations Development Program in Bosnia and Herzegovina; Ms. Gyongyver Jakab, Fund Portfolio Manager, Eastern Europe and Central Asia and Ms. Natalya Bogach, Program Officer, The Global Fund to Fight AIDS, Tuberculosis and Malaria; Dr. Nermana Mehic–Basara, Director of the Institute for Addiction Diseases of Sarajevo Canton; Mr. Denis Dedajic, Director of the Association Margina from the Federation of BiH; Mr. Srdjan Kukolj, Director of Action Against AIDS from the Republic of Srpska.
more
Ce plan stratégique 2013- 2017 s’inscrit dans la continuité du précédent et a pour but de contribuer à la réduction de la charge de la tuberculose au Sénégal d’ici 2015 conformément aux Objectifs du Millénaire (OMD 6 Cible 8) et aux cibles du partenariat Halte à la tuberculose.
Les i...nterventions porteront, principalement, sur les orientations stratégiques déclinées lors de la revue externe. Elles seront axées sur la poursuite d’une stratégie DOTS de qualité, le renforcement des interventions communautaires et la prise en charge des grands défi s (TB/VIH, TBMR, TB de l’enfant et le contrôle de l’infection). Durant cette période, l’implication des prestataires du privé sera accentuée et des stratégies de communication porteuses d’impact seront menées.
L’atteinte des objectifs de ce plan stratégique nécessitera une importante mobilisation de ressources et un plaidoyer fort sera mené auprès de tous les partenaires du secteur santé et en dehors.
more
La présente Stratégie pour des infrastructures sanitaires de qualité en Afrique2021-2030 (SISQA) répond à une demande des gouverneurs de la Banque africaine de développement (la BAD ou la Banque) invitant l’institution à définir son rôle dans la lutte contre les déficits d’infrastructu...res sanitaires en Afrique, en s’appuyant sur son expertise en matière de développement des infrastructures. Cette demande reconnaît que la santé joue un caractère central dans l’amélioration de la qualité de vie des Africains et l’opportunité de réaliser leur potentiel. Elle répond également à la demande croissante des pays membres régionaux (PMR), qui souhaitent que la Banque les aide à combler les lacunes en matière d’infrastructures sanitaires nationales, que la crise de la COVID-19 et d’autres crises sanitaires ont mises en évidence.
more
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...tems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
more
National Tuberculosis Programme and Senior Paediatricians
This guideline was first developed in 2007 but further updated in 2012 and 2016 to ensure the use of the latest evidence-based international recommendations on childhood TB. The guidelines will fill the gaps in a systematic approach to T...B in children and will help to achieve an internationally recommended standard of care at all levels of the health system in Myanmar.
more
Accessed 15th of October 2015
The Democratic Republic of Timor-Leste has the highest TB incidence rate in the South East Asian Region - 498 per 100,000, which is the seventh highest in the world. In Timor-Leste TB is the eighth most common cause of death.
The salient observations are as follows:
In 2018, 487 (12.5%) of the... 3906 notified TB patients were tested for RR-TB and only 12 lab confirmed RR-TB patients were initiated on standard MDR-TB treatment of 20-months duration, (a 3-fold increase in RR-TB detection compared with 2017). This amounts to treatment coverage of only 17% of 72 estimated MDR/RR-TB among notified TB patients (3906) and 5% of 240 estimated incident MDR-TB patients as compared to 62% treatment coverage of 6300 incident drug sensitive TB patients estimated in TLS. The treatment success in the 2016 annual cohort of 6 MDR-TB patients has been reported at 83%. 80% of TB patients know their HIV Status with around 1% TB-HIV co-infection, 37/ 77 (48%) TB-HIV Co-infection Detected. Of the 387 PLHIV currently alive on ART, exact status on TB screening and testing is unknown. % of PLHIV newly enrolled in HIV care who received IPT is not known.
In 2018, the mortality rate for TB was 94 deaths per 100,000 people (1200 per annum) in TL with an increasing mortality trend (Figure 1), despite TB services being available for nearly two decades.
A survey of catastrophic costs due to TB (2016) highlights that 83% of TB patients are reported to be facing catastrophic costs due to the disease. This is the highest rate in the world.
more